Pharmaceutical Executive

In today’s Pharmaceutical Executive Daily, we cover Biogen’s acquisition of Alcyone Therapeutics to expand its drug delivery solutions, the FDA’s expanded approval of Incyte’s Opzelura for atopic dermatitis in young children, and Pfizer’s move to acquire Metsera to strengthen its obesity and cardiovascular pipeline.

In today’s Pharmaceutical Executive Daily, we cover how pharma companies can scale AI pilots into enterprise-wide value, GSK’s plan to invest $30 billion in U.S. biopharma capacity, and Novo Nordisk’s clinical trial success with oral Wegovy.

In today’s Pharmaceutical Executive Daily, we explore how AI is disrupting higher education and career pathways, AllRock Bio’s $50 million Series A funding to advance its lead molecule, and FDA warning letters issued to Novo Nordisk, Eli Lilly, and Hims over misleading drug advertising.

In today’s Pharmaceutical Executive Daily, we cover Lilly’s orforglipron as a prime candidate for FDA fast-track approval, Merck and Daiichi Sankyo’s breakthrough therapy designation for R-DXd in ovarian cancer, and Novo Nordisk’s EU approval of Rybelsus for reducing cardiovascular risk.

Today's episode covers the president’s call to lower drug costs for patients, the compliance and operational pressures facing pharmaceutical manufacturers, and a White House plan to restrict treatments discovered in China.

In today’s Pharmaceutical Executive Daily, we cover Lundbeck’s restructuring affecting more than 600 international employees, Novo Nordisk’s global plan to cut 9,000 jobs, and former President Trump’s push to rein in pharmaceutical direct-to-consumer advertising.

In today’s Pharmaceutical Executive Daily, we explore strategies to strengthen pharma sales messaging, the role of AI-driven simulations in field rep training, and the FDA’s updated Green List restricting ingredients used in GLP-1 compounding.

In today’s Pharmaceutical Executive Daily, we will recap the top stories of the week, exploring the current state of the GLP-1 market, review major pharmaceutical layoffs shaping 2025, and cover Pfizer’s response to political pressure on COVID-19 vaccine safety evidence.

In today’s Pharmaceutical Executive Daily, we cover political pressure on Moderna and Novavax to release COVID-19 vaccine evidence, a deep dive into the evolving GLP-1 market, and Sanofi’s share decline following disappointing Phase III results for Amlitelimab.

In today’s Pharmaceutical Executive Daily, we cover Pfizer’s response to political pressure over COVID-19 vaccine safety data, Cheryl Reicin’s outlook on future GLP-1 investment, and Novartis’ $5.2 billion acquisition of Argo Biopharmaceuticals.

In a turbulent era for biopharma, leadership demands clarity, resilience, and adaptability. In this candid podcast conversation with Pharm Exec , Ken Banta, founder and CEO of The Vanguard Network, shares high-level insights on what CEOs can do to thrive amid the disruption—from regulatory agility to cultural resilience. The corporate strategy expert explains why the best leaders are the best lear...

In this week’s Pharmaceutical Executive Weekly, we cover CSL’s decision to cut 15% of its U.S. workforce and close 22 plasma centers, Pfizer’s Phase 3 trial failure in sickle cell disease, and Eli Lilly’s new LillyDirect program expanding full-dose Zepbound access for obesity patients.

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, discusses strategies to address underrepresentation in phase III psoriasis trials. She also talks about Takeda's partnerships with community stakeholders like Inside Edge, Black Health Matters, and Hispanic Communication Global Network to help improve engagement, address operational barriers by incorporating multicultural ima...

In this Pharmaceutical Executive podcast epsiode, Peter Ax, Founder & CEO of UpScriptHealth, discusses:  The impact of tariffs on the pharmaceutical industry, highlighting branded and generics medications How tariffs could lead to strategic supply chain changes, including potential US manufacturing shifts.  How digital health platforms, like UpScriptHealth, can help reduce friction and costs i...

In this episode of the Pharmaceutical Executive podcast, Jennifer Butler, Chief Commercial Officer of Pleio, discusses: The threat of misinformation to public health and how emotional appeal plays a part Where patients are turning for trustworthy health information Strategies that can be used to verify information Pharma's role in helping to ensure patients have access to health insights they can...

In this episode of the Pharmaceutical Executive Podcast, CEO and Founder of Sooth, Ian Baer, is back to discuss:  The growing distrust in social media Why people trust friends and influencers over companies The EMA's departure from X  Concerns about information accessibility The healthcare industry's trust gap  "Dark Social" and SO MUCH MORE! Pharmaceutical Executive  has a brand new look! Click t...

In this episode of the Pharmaceutical Executive podcast, Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence. By utilizing patient-level data and predictive modeling, AI can identify individual needs and preferences, tailoring interventions to optimize treatment outcomes. This personalized approach addresses the common challenges of...

In this episode of the Pharmaceutical Executive podcast, Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility ( @md.lawrence.werlin on TikTok ), discusses the challenges of addressing fertility misinformation on social media. He emphasizes the importance of providing accurate and reliable information and encourages patients to consult with healthcare professionals. He also discusses the ethical cons...

In this episode of the Pharmaceutical Executive podcast, Shubh Goel, Head of Immuno-Oncology and Gastrointestinal Tumors, US Oncology Business Unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer, an...

UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss: Counterfeit weight loss drugs (particularly fake Ozempic) and potential health risks What can be done to raise awareness among consumers about the dangers of counterfeit medications Ways increase access to legitimate weight loss medications, especially for those in underserved communities and much more...

Brian Hillberdink, EVP, LEO Pharma and President of LEO Pharma's US affiliate, discusses how is they're positioning to capitalize on the unmet needs in other specific therapeutic areas, their approach to orphan drug development, challenges and opportunities adapting to the US market, and more.

In this episode of the Pharmaceutical Executive podcast, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon discusses: The broader societal implications of these maternal health issues highlighted in The Commonwealth Fund study The most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make Specific eff...